Evaluation of anti-inflammatory effect of anti-platelet agent-clopidogrel in experimentally induced inflammatory bowel disease

Indian Journal of Pharmacology

Volumn 44, Issue 6, 2012, Pages 744-748

  Patel, Samir H ^a   Rachchh, Manish A ^a   Jadav, Pinakin D ^a  

^a S J Thakkar Pharmacy College   (India)

Author keywords

Antiplatelet agent; clopidogrel; IBD; Oxazolone; TNBS

Indexed keywords

2,4,6 TRINITROBENZENE SULFONIC ACID; ALCOHOL; CLOPIDOGREL; MYELOPEROXIDASE; OXAZOLONE; PREDNISOLONE; SALAZOSULFAPYRIDINE; TRINITROBENZENESULFONIC ACID; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BODY WEIGHT; CONTROLLED STUDY; CROHN DISEASE; ENTERITIS; ENZYME ACTIVITY; FEMALE; MALE; NONHUMAN; RAT; SCORING SYSTEM; ULCERATIVE COLITIS;

ANIMALS; ANTI-INFLAMMATORY AGENTS; COLITIS, ULCERATIVE; CROHN DISEASE; FEMALE; MALE; OXAZOLONE; PEROXIDASE; PLATELET AGGREGATION INHIBITORS; RATS; RATS, SPRAGUE-DAWLEY; RATS, WISTAR; TICLOPIDINE; TRINITROBENZENESULFONIC ACID;

EID: 84869995089     PISSN: 02537613     EISSN: 19983751     Source Type: Journal    
DOI: 10.4103/0253-7613.103278     Document Type: Article

References (25)

1. Stenson WF, Korzenik J. In: Textbook of gastroenterology. 4thed. Philadelphia: Lippincott Williams & Williams; 2003. p. 1699-759.
2. Herfindal ET, Gourley DR. In: Herfindal ET, editor. Textbook of therapeutics. 6th ed. Philadelphia: Williams and Wilkins Publication; 1996. p. 483-502.
3. Loftus EV. Clinical epidemiology of inflammatory bowel disease: Incidence, prevalence and environmental influences. Gastroenterology 2004;126:1504-17.
4. Akobeng AK, Gardener E. Oral 5-aminosalicylic acid for maintenance of medically-induced remission in Crohn's disease. Cochrane Database Syst Rev [Internet]. Available from: http://www. Cochrane.org/reviews/en/CD003715.html. [Last cited in 2005].
5. Sandborn WJ, Lofberg R, Feagan BG. Budesonide for maintenance of remission in patients with Crohn's disease in medically induced remission: A predetermined pooled analysis of four randomized, double-blind, placebo-controlled trials. Am J Gastroenterol 2005;100:1780-7.
6. Winther KV, Jess T, Langholz E. Survival and cause-specific mortality in ulcerative colitis: Follow-up of a population-based cohort in Copenhagen County. Gastroenterology 2003;125:1576-82.
7. Louis E, Collard A, Oger AF. Behavior of Crohn's disease according to the Vienna classification: Changing pattern over the course of disease. Gut 2001;49:777-82.
8. Morowitz DA, Allen LW, Kirsner JB. Thrombocytosis in chronic inflammatory bowel disease. Ann Intern Med 1968;68:1013-21.
9. Webberley MJ, Hart MT, Melikian V. Thromboembolism in inflammatory bowel disease: Role of platelets. Gut 1993;34:247-51.
10. Fagerstam JP, Whiss PA, Strom M, Andersson RG. Expression of platelet P-selectin and detection of soluble P-selectin, NPY and RANTES in patients with inflammatory bowel disease. Inflamm Res 2000;49:466-72.
11. Lamprecht A, Yamamoto H, Takeuchi H, Kawashima Y. Nanoparticles enhance therapeutic efficiency by selectively increased local drug dose in experimental colitis in rats. J Pharmacol Exp Ther 2005;315:196-202.
12. Fermin SD, Julio G, Jose AR, Antonio Z. Effect of Quercitrin on acute and chronic experimental colitis in the rat. J Pharmacol Exp Ther 1996;278:771-9.
13. Li XL, Cai YQ, Qin H, Wu YJ. Therapeutic effect and mechanism of proanthocynidins from grape seeds in rats with TNBS induced ulcerative colitis. Can J Physiol Pharmacol 2008;86:841-9.
14. Wei DG, Liu SP, Yu BP, Wu DF, Luo SH, Yu JP, et al. Ameliorative effects of sodium ferulate on experimental colitis and their mechanisms in rats. World J Gastroenterol 2003;9:2533-8.
15. Miller AD, Rampton DS, Chander CL, Claxson AW, Blades S, Coumbe A, et al. Evaluating the antioxidant potential of new treatments for inflammatory bowel disease using a rat model of colitis. Gut 1996;39:407-15.
16. Ormrod DJ, Harrison GL, Milier TE. Inhibition of neutrophil myeloperoxidase activity by selected tissues. J Pharmacol Methods 1987;18:137-42.
17. Kanodia L, Borgohain M, Das S. Effect of fruit extract of fragaria Vesca L. on experimentally induced inflammatory bowel disease in albino rats. Indian J Pharmacol 2011;43:18-21.
18. Selve N, Wohrmann T. Intestinal inflammation in TNBS sensitized rats as a model of chronic inflammatory bowel disease. Mediators Inflamm 1992;1:121-6.
19. Hamamoto N, Maemura K, Hirata I, Murano M, Sasaki S, Katsu K, et al. Inhibition of dextran sulphate sodium (DSS)-induced colitis in mice by intracolonically administered antibodies against adhesion molecules (endothelial leucocyte adhesion olecule-1 (ELAM-1) or intercellular adhesion molecule-1 (ICAM-1). Clin Exp Immunol 1999;117:462-8.
20. Mannaioni PF, Di BM, Masini E. Platelets and in ammation: Role of platelet-derived growth factor, adhesion molecules and histamine. In Inflamm Res 1997;46:4-18.
21. Lewis CD, Olson NE, Raines EW. Modulation of smooth muscle proliferation in rat carotid artery by platelet-derived mediators and fibroblast growth factor-2. Platelets 2001;12:352-8.
22. Danese S, Katz J, Saibeni S, Papa A, Gasbarrini A, Vecchi M, et al. Activated platelets are the source of elevated levels of soluble CD40 ligand in the circulation of inflammatory bowel disease patients. Gut 2003;52:1435-41.
23. Danese S, Scaldaferri F, Papa A, Pola R, Sans M, Gasbarrini G, et al. Platelets: New players in the mucosal scenario of inflammatory bowel disease. Eur Rev Med Pharmacol Sci 2004;8:193-8.
24. Gkaliagkousi E, Passacquale G. Platelet activation in essential hypertension: Implications for anti-platelet treatment. Am J Hypertens 2010;23:229-36.
25. Storey RF, Wilcox RG, Heptinstall S. Comparison of the pharmacodynamic effects of the platelet ADP receptor antagonists clopidogrel and AR-C69931MX in patients with ischemic heart disease. Platelets 2002;13:407-13.